Fig. 4

circ_0084927 enhanced cervical carcinogenesis by inhibiting miR-1179. a The transfection efficiency of si-circ_0084927 and miR-1179 inhibitor in transfected cells was detected by qRT-PCR. b The proliferation of HeLa and C-33A cells transfected with si-NC, si-circ_0084927, miR-1179 inhibitor or si-circ_0084927 plus miR-1179 inhibitor was determined by CCK-8 assay. c BrdU incorporation assay was used to analyze the proliferation of HeLa and C-33A cells transfected with si-NC, si-circ_0084927, miR-1179 inhibitor or si-circ_0084927 plus miR-1179 inhibitor. d The cell cycle progression of HeLa and C-33A cells transfected with si-NC, si-circ_0084927, miR-1179 inhibitor or si-circ_0084927 plus miR-1179 inhibitor was identified by flow cytometry assay. e Cell–matrix adhesion assay was used to determine the adhesion ability of HeLa and C-33A cells transfected with si-NC, si-circ_0084927, miR-1179 inhibitor or si-circ_0084927 plus miR-1179 inhibitor. f The apoptosis of HeLa and C-33A cells transfected with si-NC, si-circ_0084927, miR-1179 inhibitor or si-circ_0084927 plus miR-1179 inhibitor was determined by the caspase 3 activation experiment. a–f The data were presented in the form of mean ± SD of three experiments. *P < 0.05, **P < 0.01, compared with the CON (blank control) group; ^#P < 0.05, ^##P < 0.01, compared with the si-circ (circ_0084927 siRNA) group